Exact Sciences Plans Layoffs as It Acquires Rights to Cancer Screening Blood Test

Exact Sciences plans layoffs as it acquires rights to cancer screening blood test

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the second time in a row with higher revenue than initially projected.

Exact Sciences acquires rights to rival Freenome’s blood-based colon cancer test

The deal ratchets up Exact’s intense competition with Guardant, which received FDA approval last year for its own colon cancer liquid biopsy

Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer

– Deal worth up to $885 million based on achievement of certain regulatory and screening guideline milestones –

Exact Sciences to acquire US rights for Freenome's blood-based CRC test

Freenome has entered an exclusive licence agreement with Exact Sciences, granting the latter the rights to commercialise Freenome's blood-based CRC screening test in the US.The post Exact Sciences to acquire US rights for Freenome’s blood-based CRC test appeared first on Medical Device Network.

Exact Sciences Acquires Rights to Freenome’s Blood-Based Colon Cancer Test for $75 Million

Exact Sciences has secured exclusive rights to a blood

Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early c...